Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Portfolio Pulse from Benzinga Newsdesk
Navidea Biopharmaceuticals has raised $1.1 million through the sale of preferred shares to new and existing investors. The funds will be used to support the completion of the company's NAV3-32 and NAV3-33 trials.

May 23, 2023 | 8:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Navidea Biopharmaceuticals raised $1.1 million through preferred shares sale, providing additional capital for NAV3-32 and NAV3-33 trials completion.
The sale of preferred shares totaling $1.1 million provides Navidea Biopharmaceuticals with additional capital to fuel the completion of their NAV3-32 and NAV3-33 trials. This funding is likely to have a positive short-term impact on the company's stock price, as it demonstrates investor confidence and supports the advancement of their trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100